Fosun expects 1H profit attributable to owners at RMB 1.5 billion-RMB 1.8 billionPUBT·1 day ago, 04:33 AM02196-6.00%00656+7.88%
Hong Kong Market Shifts: The Tug-of-War Between Nvidia Leverage and High-Yield ETFsGlobal Report·1 day ago, 04:18 AM02196-6.00%098600.00%
Hong Kong's Niche Sectors Signal Structural Shifts: How Institutions Are RepositioningGlobal Report·2 days ago, 04:13 AM01099-0.28%01513-0.31%
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement | VRAX Stock NewsStockTitan·Jul 15 at 10:30 PMVRAX-5.22%600196+0.74%
Virax Biolabs signs Fosun Diagnostics supply deal for ImmuneSelect in six Southeast Asian marketsPUBT·Jul 16 at 06:33 AMVRAX-5.22%02196-6.00%
Fosun Pharma Shenzhen wins China approval to start Phase I trial of FXR0906 for hypertriglyceridemiaPUBT·Jul 15 at 05:14 AM02196-6.00%600196+0.74%
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Gets a Hold from HSBCTip Ranks·Jul 13 at 07:27 PM600196+0.74%02196-6.00%
Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watchrttnews·Jul 9 at 09:55 PMFBRX+1.00%CNTB+3.90%
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics | VRAX Stock NewsStockTitan·Jul 8 at 10:30 PMVRAX-5.22%02196-6.00%
